Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Concurrent Investment Advisors LLC

Concurrent Investment Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 831 shares of the biopharmaceutical company’s stock after acquiring an additional 37 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $874,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in REGN. West Paces Advisors Inc. lifted its position in Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares during the period. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $26,000. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $28,000. Lynx Investment Advisory acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. Finally, Family Firm Inc. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The disclosure for this sale can be found here. Insiders sold a total of 22,239 shares of company stock valued at $23,933,880 over the last quarter. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $1,184.69 on Monday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20. The stock has a market cap of $130.54 billion, a price-to-earnings ratio of 35.00, a price-to-earnings-growth ratio of 3.13 and a beta of 0.13. The business has a fifty day moving average of $1,102.92 and a 200-day moving average of $1,013.16. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same period in the previous year, the firm posted $8.79 earnings per share. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on REGN. Canaccord Genuity Group reaffirmed a “buy” rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. JPMorgan Chase & Co. increased their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Argus increased their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Finally, Piper Sandler increased their target price on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research note on Friday, August 23rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,108.45.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.